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BK AND JC POLYOMAVIRUS VIREMIA IN ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANT PATIENTS: THERAPEUTIC ROLE OF FOSCARNET
Oholendt, M.S., Kamble, R.T., Carrum, G. Center for Cell and Gene
Therapy, Baylor College of Medicine and The Methodist Hospital, Hous-
ton, TX.
Background: The human polyomaviruses (JCV and BKV) are
ubiquitous. Infection acquired early in life remains latent in the
B-lymphocytes of immunocompetent hosts. The exact significance
of BKV and JCV reactivation following hematopoietic cell trans-
plant (HCT) is unknown but is increasingly being implicated in
hemorrhagic cystitis/nephritis (both BKV and JCV) as well as pro-
gressive multifocal leukoencephalopathy (JCV). Although cidofo-
vir, with accompanying nephrotoxicity, is increasingly used for
BKV-related hemorrhagic cystitis/nephritis, therapy for JCV is
not currently established. Methods: Incidental observation of de-
cline in the BKV and JCV viremia while receiving foscarnet
(FOS) for herpes infection (CMV, VZV, HHV-6) in 4 HCT pa-
tients form the basis of this report. Quantification of BKV and
JCV viremia was obtained using polymerase chain reaction
(qPCR). Testing was repeated weekly or as indicated during the
course of FOS. Results: Four patients with eleven initial or reacti-
vation FOS-treatment episodes were recorded. Themedian age of 3
males and 1 female was 43.5 years (range 19–60). BKV/JCV reacti-
vation occurred at a median of 73.5 days (range 33–398) which was
asymptomatic in 3 patients; one patient had grade II hemorrhagic
cystitis. FOS incidentally resulted in marked reduction in BKV
and JCV viremia; the median time to $ 50% reduction in viremia
was 8 days for both BKV and JCV. The best response for BKV
and JCV was a median reduction of 89% (range 27–100) and 63%
(range 26–98) in DNA copies respectively. Conclusions: Given
the high incidence of nephrotoxicty with cidofovir, our observation
warrants further assessment of FOS for the treatment of BKV and
JCV infections in the allogeneic HCT patient.271
RECOMBINANT FACTOR 7A IN PAEDIATRIC STEM CELL TRANSPLANT
SUPPORTIVE CARE
Jessop, M.E., Lockwood, L.R., Hallahan, A., Smith, E.K., Little, M.A.
Royal Childrens Hospital, Brisbane, Queensland, Australia.
Recombinant factor7a (r7a) is structurally almost identical to
plasma derived VIIa and promotes haemostasis by activating factors
IX and X when complexed to tissue factor. There is established use
of r7a in trauma, surgical and obstetric bleeding, patients with ac-
quired haemophilia, and in the management of haemophilia pa-
tients with inhibitors to factor VIII or IX. Increasing use of this
drug has developed in haematology/oncology practice with varied
outcomes. An audit of the use of r7a in the Stem Cell Transplant
Unit at Royal Children’s Hospital Brisbane was conducted.
Ten treatment episodes in six patients were identified (one pa-
tient pre stem cell collection, four patients immediately post
BMT and one patient 12 mths post BMT). In the patient who de-
veloped intrathoracic bleeding post vascath insertion for stem cell
collection, the bleeding responded to r7a in combination with other
haemostatic agents with complete recovery. The four patients in the
immediate post BMTperiod weremanaged during five bleeding ep-
isodes with a wide range of doses of r7a. Indications for r7a in these
patients were bleeding due to: GVHD (3), mucositis (1), pulmonary
haemorrhage (1). Three of these patients had GVHD with two of
the three patients achieving a partial response to treatment and
one without response. All three of these patients died with active
bleeding. The fourth patient had two bleeding episodes (life threat-
ening mucosal and pulmonary haemorrhage) and responded to
treatment during both episodes.One patient developed refractory immune mediated thrombocy-
topenia 12 months post allogeneic BMT for ALL. He received r7a
during 4 separate treatment episodes (gastrointestinal bleeding,
subdural haemorrhage, mucosal and gastrointestinal bleeding, dur-
ing splenectomy). Bleeding was controlled on all four occasions.
All patients with refractory GVHD and gastrointestinal bleeding
failed to have sustained responses and the outcomes in this group
were universally poor. In those patients with reversible underlying
pathology r7a was useful in sustaining haemostatic control with
a good overall survival. r7a is an exciting addition to our haemostatic
agents but the varied outcomes and high cost of this drug indicate
that further study and development of guidelines for use in stem
cell transplant is warranted.272
CYTOMEGALOVIRUS (CMV) SPECIFIC CYTOTOXIC T LYMPHOCYTES
FROM A CMV SERO-NEGATIVE DONOR FOR PERSISTENT CMV INFEC-
TION POST-TRANSPLANT
Lucas, K.1, Cowan, M.2, Horn, B.2, Dunham, K.1, Bao, L.1 1 Penn State
Children’s Hospital, Hershey, PA; 2 UCSF Children’s Hospital, San
Francisco, CA.
Cytomegalovirus (CMV) reactivation following an allogeneic
stem cell transplant (SCT) can be a challenging clinical situation
when the stem cell donor is serologically negative for CMV or the
graft has been T cell depleted.We present a patient with myelodys-
plastic syndrome who received a T cell depleted, haplo-identical
SCT from his CMV sero-negative father and developed persistent
CMV infection, uveitis, and encephalitis, despite several months
of anti-viral agents, including ganciclovir, foscarnet, and cidofovir.
He had improvement in his encephalitis but had persistent CMV vi-
remia despite these agents. His CMV sero-negative father received
a single vaccination with theTowne strain of CMV (fromDr. Stuart
Adler, Medical College of Virginia), and 10 days later CMV specific
cytotoxic T lymphocytes (CTL) were expanded using a pool of
15-merCMVpp65 overlapping peptides.CMVpp65CTLwere stim-
ulated once with peptide pulsed monocytes, had pp65 specific cyto-
toxicity, and lacked auto- or allo-reactivity by chromium release
assay. All antivirals were discontinued two weeks prior to his
CTL infusion due to pancytopenia, which was thought to be due
to prolonged use of cidofovir. He received a single dose of 2 
105 CMVCTL pp65/kg. CMV viral load decreased from 1900 cop-
ies/ml pre-infusion to 100 copies/ml three weeks post-infusion,
which was followed by three consecutive weeks with no detectable
CMV by PCR. All clinical signs of CMV infection have resolved,
without the use of anti-CMV medications. CMV pp65 specific cy-
totoxicity was in the normal range by 4 weeks post-infusion. Unfor-
tunately our patient was diagnosed with recurrent leukemia at 3
weeks post-infusion, precluding long-term follow-up of his immune
status. Considering the fact that this patient did not receive any
other intervention for his CMV infection during this time period,
it seems possible that his clinical, immunologic and virologic im-
provement could have occurred as a result of the CMV CTL infu-
sion. The vaccination was well tolerated by the donor, and the
culture method was relatively simple, making this a strategy that
can be applied in similar situations.273
AIR FILTRATION IN STEM CELL TRANSPLANT UNITS: IS IT ALWAYS NEC-
ESSARY?
Wood, C.E., Johnson, L.R., Carter, J.M., Anthony, B. Wellington Hos-
pital, Wellington, New Zealand.
Infections are a significant cause of morbidity andmortality in re-
cipients of allogeneic haematopoietic stem cell transplants. Interna-
tional guidelines exist regarding prevention and treatment of
bacterial, viral and fungal infections in this setting. The use of
HEPA filtered air is often mandated by best practise guidelines to
reduce infection, especially Aspergillus and other spore born fungi.
The evidence basis for this is debatable and implementation of these
Poster Session I 101recommendations is often expensive and they take little account of
geographical variance in the incidence of such organisms.
The Wellington Transplant Unit has historically had a very low
incidence of fungal infections. Recently the unit has been exposed to
major dust contamination from building demolition and rebuilding
on the hospital campus. To obviate this threat the transplant unit
has nursed patients in newly commissioned HEPA filtered rooms.
This project has been prospectively monitored with environmental
surveillance cultures and recording of patient infections. Data will
be presented showing a very low environmental contamination
and a low patient infection rate. This challenges the universal rec-
ommendation for the need for protected rooms. This conclusion
is further supported by a care model that emphasises early patient
discharge to a day care unit which does not have protected rooms.274
LEVOFLOXACINE ANTIBACTERIAL PROPHYLAXIS FOR PATIENTS
TREATED WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS
STEM CELL TRANSPLANTATION
Casas, C.P., Abello, V., Rosales, C., Pedraza, E., Esguerra, H.,
Linares, A., Rosales, M.L. Clınica de Marly, Bogota, Colombia.
Bacterial infections are a major cause of morbility and mortality
in neutropenic patients after high dose chemotherapy. We per-
formed a retrospective analysis to compare results before and after
instituting a prophylactic antibacterial regimen with Levofloxacine,
in patients undergoing an auto-SCT.
Here we analyze data for patients transplanted from July 2006
and June 2007 (group A), who received Levofloxacine as antibacte-
rial prophylaxis and compared the results with a control group
transplanted from July 2005 to June 2006 (group B), who didn’t re-ceive Levofloxacine. Both groups received similar conditioning reg-
imens and support treatment.
Indication for auto-SCTwereHodgkin Lymphoma, NonHodg-
kin Lymphoma, Multiple Myeloma and Acute Myeloid Leukemia.
There were 36 patients in group A and 24 in group B. Table 1 com-
pares the results in both groups.
In this series of 84 patients, Levofloxacine prophylaxis reduced
the percentage of patients with fever, hospital stay, days of neutro-
penic fever, days of antibiotic uses, number of antibiotics per pa-
tient, % of patient receiving antimicotics. This results are in
accordance with recent publish papers on that subject.Characteristics of patients by groups
Characteristis Group A Group B# Patients 36 24
Age (years)* 44 (12–67) 35.1 (6–68)
M/F 22/14 18/6
Hospital Stay (days)* 23 (14–37) 27 (16–44)
% patients with fever 69.4% 95.8%
Neutropenic fever
(days)*3.6 5.3Antibiotic use (days)* 18 (0–69) 27 (4–77)
Number antibiotics/
patient*2.3 (0–6) 3.4 (1–6)% patients treated with
antimicotics27% 50%Mortality before day 30 0/36 2/24*Mean (range).
